News Column

Data on DNA Vaccines Reported by Researchers at Food Research Institute (Comparative analysis of enzymatically produced novel linear DNA constructs...

August 13, 2014



Data on DNA Vaccines Reported by Researchers at Food Research Institute (Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines)

By a News Reporter-Staff News Editor at Vaccine Weekly -- Current study results on Biotechnology have been published. According to news reporting originating from Surrey, United Kingdom, by NewsRx correspondents, research stated, "The use of DNA to deliver vaccine antigens offers many advantages, including ease of manufacture and cost. However, most DNA vaccines are plasmids and must be grown in bacterial culture, necessitating elements that are either unnecessary for effective gene delivery (for example, bacterial origins of replication) or undesirable (for example, antibiotic resistance genes)."

Our news editors obtained a quote from the research from Food Research Institute, "Removing these elements may improve the safety profile of DNA for the delivery of vaccines. Here, we describe a novel, double-stranded, linear DNA construct produced by an enzymatic process that solely encodes an antigen expression cassette, comprising antigen, promoter, polyA tail and telomeric ends. We compared these constructs (called 'Doggybones' because of their shape) with conventional plasmid DNA. Using luciferase-expressing constructs, we demonstrated that expression levels were equivalent between Doggybones and plasmids both in vitro and in vivo. When mice were immunized with DNA constructs expressing the HIV envelope protein gp140, equivalent humoral and cellular responses were induced. Immunizations with either construct type expressing hemagluttinin were protective against H1N1 influenza challenge."

According to the news editors, the research concluded: "This is the first example of an effective DNA vaccine, which can be produced on a large scale by enzymatic processes."

For more information on this research see: Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines. Gene Therapy, 2014;21(7):645-652. Gene Therapy can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Gene Therapy - www.nature.com/gt/)

The news editors report that additional information may be obtained by contacting A.A. Walters, Touchlight Genet Ltd, Leatherhead Food Res Inst, Leatherhead, Surrey, United Kingdom. Additional authors for this research include E. Kinnear, R.J. Shattock, J.U. McDonald, L.J. Caproni, N. Porter and J.S. Tregoning (see also Biotechnology).

Keywords for this news article include: Biotechnology, Surrey, Europe, DNA Research, DNA Vaccines, United Kingdom, Bacterial Vaccines, Synthetic Vaccines, Biological Products

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Vaccine Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters